Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several general safety statements about adverse reactions are broadly consistent with label themes, but multiple claims are unsupported by the supplied label excerpts (especially indication specifics, dosing-cycle structure, and prodrug/5-FU mechanism as stated). Important label-specific safety guidance included in the excerpts (DPD testing/avoidance in complete deficiency and vitamin K antagonist interaction with INR monitoring) is omitted.
Category Scores
Accurate Statements
Hand-foot syndrome can occur during capecitabine therapy, with symptoms including redness, swelling, pain, or peeling on palms/soles.
Not directly supported by the provided excerpts.
Diarrhea, nausea, and mouth sores can occur during capecitabine therapy.
Supported generally by the excerpt mentioning serious adverse reactions including mucositis and diarrhea in DPD deficiency (Section 5.1), but not specifically as a general counseling list.
Fatigue and lowered blood counts can occur during capecitabine therapy.
Lowered blood counts/neutropenia are referenced as serious adverse reactions in DPD deficiency (Section 5.1); fatigue is not referenced in provided excerpts.
Lowered blood counts can increase infection or bleeding risk.
Not explicitly supported in provided excerpts; only neutropenia is mentioned (Section 5.1), and bleeding risk is discussed only with vitamin K antagonists.
Dose adjustments may be needed during capecitabine therapy.
Supported for partial DPD deficiency: individualize dosage and modify based on tolerability (Sections 5.1 and 2.1).
Unsupported Statements
Capecitabine is an oral chemotherapy medicine used to treat certain cancers, including breast, colon, and rectal cancers.
No indication-specific information is present in the supplied excerpts.
Capecitabine is taken in cycles as prescribed by an oncology team.
No cycle-based dosing schedule is present in the supplied excerpts.
Capecitabine is a prodrug.
No prodrug description is present in the supplied excerpts.
The body converts capecitabine into 5-fluorouracil (5-FU).
No conversion/mechanism details are present in the supplied excerpts.
5-fluorouracil (5-FU) interferes with cancer-cell growth.
No mechanism description is present in the supplied excerpts.
Oncology teams advise patients when to call urgently during capecitabine therapy (for example, fever or severe diarrhea).
No patient-call urgency guidance is present in the supplied excerpts.
Capecitabine dosing and timing depend on the cancer being treated and the regimen selected by an oncologist.
No dosing-logic by cancer type/regimen is present in the supplied excerpts.
Capecitabine is taken by mouth in scheduled doses.
No administration-by-mouth/scheduled dosing statement is present in the supplied excerpts.
Capecitabine is taken for a set number of days followed by a rest period in repeating cycles.
No day/rest cycle pattern is present in the supplied excerpts.
Capecitabine is converted in the body to 5-FU, which is the active chemotherapy agent.
No conversion/mechanism details are present in the supplied excerpts.
Low appetite and taste changes can occur during capecitabine therapy.
No appetite/taste change adverse reactions are present in the supplied excerpts.
Low appetite and taste changes can occur during capecitabine therapy.
No appetite/taste change adverse reactions are present in the supplied excerpts.
Contradictions
Low
AI Statement
Lowered blood counts can increase infection or bleeding risk.
Label Reference
Sections 5.1 and 5.2 only support infection risk via neutropenia and bleeding risk specifically with vitamin K antagonists; bleeding risk is not stated for capecitabine-induced cytopenias in provided excerpts.
Important Omissions
Prior to initiating XELODA, test patients for DPYD genetic variants unless immediate treatment is necessary; avoid XELODA in patients with certain homozygous/compound heterozygous DPYD variants resulting in complete DPD deficiency; no XELODA dose proven safe in complete DPD deficiency; individualize dosage and modify based on tolerability for partial DPD deficiency.
Importance:
High
Concomitant use with vitamin K antagonists (e.g., warfarin) increases risk of bleeding (including death); monitor INR more frequently and adjust vitamin K antagonist dose as appropriate; events may occur within days and up to 1 month after stopping XELODA.
Importance:
High
Patient counseling to immediately contact healthcare provider for signs/symptoms of bleeding while taking XELODA with vitamin K antagonists.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Omission of label-specific high-impact safety guidance in the provided excerpts (DPD testing/avoidance for complete DPD deficiency and management of vitamin K antagonist interaction with INR monitoring) could reduce patient safety relative to the prescribing information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Missing key boxed/sectioned label safety content from the provided excerpts (DPD deficiency testing/avoidance and vitamin K antagonist interaction with INR monitoring), plus several mechanism/indication/cycle/dosing claims that are unsupported by the supplied excerpts.
Suggested Improvement
Restrict statements to what is supported by the provided label excerpts, and explicitly include (1) DPYD testing/avoidance in complete DPD deficiency and (2) increased bleeding risk with vitamin K antagonists with INR monitoring and dose adjustment guidance.